VYNE Therapeutics Inc VYNE 深 滬
已收盤 07-29 16:00:00 美东时间
28.56
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 28.56
- 總市值 9.53亿
- 52周最高 28.56
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 -6.096
- 委 比 0.00%
- 總股本 3338.51万
- 歷史最高 143475.879
- 量 比 0
- 振 幅 0.00%
- 歷史最低 -6.096
- 每 手 1
- 風險率 7.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics Inc. announced a 1-for-50 reverse stock split in anticipation of its merger with Yarrow Bioscience, Inc. The reverse split will reduce VYNE’s outstanding shares from ~33.4 million to ~0.7 million. The combined company, renamed Yarrow Bioscience, Inc., will trade on Nasdaq under the ticker "YARW" starting July 27, 2026. Additionally, VYNE declared a special cash dividend of $17.3 million, or ~$0.40242 per share, payable on July 2...
07-21 12:00
VYNE Therapeutics Announces Special Cash Dividend Of $0.38/Share
VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Yarrow Bioscience, Inc. ("Yarrow") pursuant to the Agreement an...
07-10 20:01
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics announced a special cash dividend of $16.5 million, or $0.38 per share, to stockholders and warrant holders of record as of July 22, 2026. The dividend is tied to the merger with Yarrow Bioscience, expected to close on July 24, 2026, subject to stockholder approval. VYNE stockholders will vote on the merger at a special meeting on July 16, 2026. Yarrow is developing therapies for autoimmune thyroid diseases, while VYNE focuses o...
07-10 12:00
VYNE Therapeutics Q1 EPS $(0.08) Beats $(0.18) Estimate, Sales $86.000K Miss $200.000K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.18) by 55.56 percent. This is a 60 percent increase over losses of $(0.20) per share from
05-16 06:14
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Agape ATP (NASDAQ:ATPC) stock rose 68.1% to $0.15 during Wednesday's r...
2025-12-18 01:06
VYNE Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement pursuant to combine with Yarrow Bioscience.
VYNE Therapeutics shares are trading higher after the company announced it ente...
2025-12-17 21:32
VYNE Therapeutics Q3 EPS $(0.17) Misses $(0.13) Estimate, Sales $169.000K Beat $100.000K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 41.38 percent increase over losses of $(0.29) per share
2025-11-06 21:29
